Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SKL2001 (frequently referred to in literature as SKL20001) is a synthetic small-molecule agonist of the canonical Wnt/β-catenin signaling pathway. It acts by directly binding to the Armadillo repeat domain (specifically repeats 3–5) of β-catenin, which competitively disrupts its interaction with the scaffold protein Axin. By preventing Axin from targeting β-catenin for phosphorylation and subsequent proteasomal degradation, SKL2001 stabilizes intracellular β-catenin, promoting its accumulation and nuclear translocation to activate downstream transcription factors. SKL2001 is widely utilized as a chemical probe in preclinical research to study mesenchymal stem cell differentiation, bone defect repair, oncology, and protective mechanisms against alcohol-induced liver injury.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SKL2001 (6284a0).